Unique ID issued by UMIN | UMIN000005860 |
---|---|
Receipt number | R000006923 |
Scientific Title | A non-randomized controlled trial examining effects of zinc-containing preparation polaprezinc on pressure ulcer healing |
Date of disclosure of the study information | 2011/06/28 |
Last modified on | 2016/11/14 23:10:29 |
A non-randomized controlled trial examining effects of zinc-containing preparation polaprezinc on pressure ulcer healing
Effects of zinc-containing preparation polaprezinc on pressure ulcer healing
A non-randomized controlled trial examining effects of zinc-containing preparation polaprezinc on pressure ulcer healing
Effects of zinc-containing preparation polaprezinc on pressure ulcer healing
Japan |
Pressure ulcer
Surgery in general | Dermatology |
Others
NO
To determine and compare the effects of zinc-containing preparation polaprezinc and its subcomponent L-carnosine on the healing of chronic pressure ulcers
Safety,Efficacy
Change in PUSH (Pressure Ulcer Scale for Healing) score
Body weight, Biochemistry, Dietary intake
Interventional
Parallel
Non-randomized
Open -but assessor(s) are blinded
No treatment
3
Treatment
Medicine |
After 4-week untreated period, polaprezinc is administered orally at a dose of 75 mg twice a day until complete healing or for a maximum of 8 weeks.
Polaprezinc is administered orally at a dose of 75 mg twice a day until complete healing or for a maximum of 8 weeks.
L-Carnosine is administered orally at a dose of 58 mg twice a day until complete healing or for a maximum of 4 weeks. For patients without complete healing within 4 weeks, from the end of 4-week period, polaprezinc is administered orally at a dose of 75 mg twice a day until complete healing or for a maximum of 8 weeks.
20 | years-old | <= |
Not applicable |
Male and Female
Patients who meet following requirements:
1) aged 20 and older
2) at least one stage 2, 3, or 4 chronic pressure ulcer according to the revised National Pressure Ulcer Advisory Panel (NPUAP) classification system
3) an estimated surface area of one ulcer is 24 square centimeters or less, as calculated with the formula: greatest length (head to toe) multiplied by greatest width (side to side) of the ulcer
4) patients who take a diet orally
5) written informed consent from patients and their families before registration to this study
1) a clinical suspicion or diagnosis of osteomyelitis
2) diabetes mellitus
3) peripheral vascular disease
4) neoplastic disease
5) acute illness (e.g., infection)
6) other severe diseases
7) patients who receive tube or parenteral feeding
8) use of steroids
9) patients who are in the terminal phase of their illness
42
1st name | |
Middle name | |
Last name | Kensaku Sakae |
The Jikei University School of Medicine
Department of Public Health and Environmental Medicine
3-25-8 Nishishimbashi, Minato-ku, Tokyo
03-3433-1111(ext.2266)
yashiohp@nifty.com
1st name | |
Middle name | |
Last name | Kensaku Sakae |
The Jikei University School of Medicine
Department of Public Health and Environmental Medicine
3-25-8 Nishishimbashi, Minato-ku, Tokyo
03-3433-1111(ext.2266)
yashiohp@nifty.com
Department of Public Health and Environmental Medicine, The Jikei University School of Medicine
None
Self funding
None
NO
医療法人慶榮会 八潮病院 (埼玉県)
特別養護老人ホーム 杜の家やしお (埼玉県)
2011 | Year | 06 | Month | 28 | Day |
Published
Completed
2008 | Year | 07 | Month | 12 | Day |
2008 | Year | 10 | Month | 01 | Day |
2013 | Year | 05 | Month | 01 | Day |
2011 | Year | 06 | Month | 28 | Day |
2016 | Year | 11 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006923